Article

In vivo I-123 IBZM SPECT imaging of striatal dopamine-2 receptor occupancy in schizophrenic patients treated with olanzapine in comparison to clozapine and haloperidol

Department of General Psychiatry, University of Vienna, Austria.
Psychopharmacology (Impact Factor: 3.99). 01/1999; 141(2):175-81. DOI: 10.1007/s002130050822
Source: PubMed

ABSTRACT We investigated the degree of striatal dopamine-2 (D2) receptor occupancy in six schizophrenic patients receiving clinically effective antipsychotic treatment with olanzapine 10-25 mg/day in comparison to patients treated with clozapine 300-600 mg/day (n = 6) or haloperidol 5-20 mg/day (n = 10). 123I Iodobenzamide (IBZM) and single photon emission computerized tomography (SPECT) were used for the visualization of striatal D2 receptors. For the quantification of striatal D2 receptor occupancy, striatal IBZM binding in patients treated with antipsychotics was compared to that in untreated healthy controls (n = 8) reported earlier. Olanzapine led to a mean striatal D2 receptor occupancy rate of 75% (range 63-85). Haloperidol-treated patients showed dose-dependently (Pearson r = 0.64; P < 0.05) a significantly higher (P < 0.05) mean occupancy rate of 84% (range 67-94). During clozapine treatment, the mean D2 receptor occupancy of 33% (range < 20-49) was significantly lower than with olanzapine (P < 0.005). The higher striatal D2 receptor occupancy of haloperidol was correlated with the incidence and severity of extrapyramidal motor side-effects (EPS). No clinical relevant EPS occurred during treatment with olanzapine or clozapine. There was no correlation between the degree of striatal D2 receptor occupancy and clinical improvement.

Full-text

Available from: Lukas Pezawas, Apr 26, 2014
1 Follower
 · 
62 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: A glassy carbon electrode was coated with a thin layer of multi-walled carbon nanotubes and subsequently was electro-polymerized with polypyrrole. The prepared electrode was used for the voltammetric determination of olanzapine (OLZ). The peak current of OLZ increases remarkably on the surface of the modified electrode. This is due to the large increase in the microscopic area of the electrode surface along with the strong adsorption of OLZ on the surface of the electrode. The film modifier was characterized by scanning electron microscopy, atomic force microscopy and cyclic voltammetry techniques. Experimental variables, such as deposited amount of nanotube suspension, pH of the supporting electrolyte, potential and time of the accumulation and the number of electro-polymerization cycles were optimized by monitoring the LSV responses toward OLZ. In the optimal conditions, the electrode showed a linear response to the concentration of OLZ within 0.02–2.00 µM range with a detection limit of 6.00 nM. The electrode shows advantages such as simple preparation, high stability and uniformity in the composite film and high sensitivity in response to the OLZ. The modified electrode has been applied for accurate determination of the trace amounts of OLZ in pharmaceutical and clinical preparations.
    RSC Advances 08/2014; 4(76). DOI:10.1039/C4RA04584J · 3.71 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Recent developments in neuroimaging have advanced the understanding of biological mechanisms underlying schizophrenia. However, neuroimaging correlates of treatment-resistant schizophrenia (TRS) and superior effects of clozapine on TRS remain unclear. Systematic search was performed to identify neuroimaging characteristics unique to TRS and ultra-resistant schizophrenia (i.e. clozapine-resistant [URS]), and clozapine's efficacy in TRS using Embase, Medline, and PsychInfo. Search terms included (schizophreni*) and (resistan* OR refractory OR clozapine) and (ASL OR CT OR DTI OR FMRI OR MRI OR MRS OR NIRS OR PET OR SPECT). 25 neuroimaging studies have investigated TRS and effects of clozapine. Only 5 studies have compared TRS and non-TRS, collectively providing no replicated neuroimaging finding specific to TRS. Studies comparing TRS and healthy controls suggest that hypometabolism in the prefrontal cortex, hypermetabolism in the basal ganglia, and structural anomalies in the corpus callosum contribute to TRS. Clozapine may increase prefrontal hypoactivation in TRS although this was not related to clinical improvement; in contrast, evidence has suggested a link between clozapine efficacy and decreased metabolism in the basal ganglia and thalamus. Existing literature does not elucidate neuroimaging correlates specific to TRS or URS, which, if present, might also shed light on clozapine's efficacy in TRS. This said, leads from other lines of investigation, including the glutamatergic system can prove useful in guiding future neuroimaging studies focused on, in particular, the frontocortical-basal ganglia-thalamic circuits. Critical to the success of this work will be precise subtyping of study subjects based on treatment response/nonresponse and the use of multimodal neuroimaging. Copyright © 2015 Elsevier B.V. All rights reserved.
    Schizophrenia Research 02/2015; 164(1-3). DOI:10.1016/j.schres.2015.01.043 · 4.43 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: In vivo studies of dopamine D-2 receptor occupancy with atypical antipsychotics have suggested good clinical efficacy at occupancy rates less than those observed with typical neuroleptics, and few extrapyramidal side effects (EPS), possibly even at high levels of D-2 occupancy. We used [I-123]IBZM-SPECT to investigate striatal D-2 receptor occupancy in 10 schizophrenic patients who were treated with both a low (5 mg) and a high dose (20 mg) of the novel antipsychotic olanzapine without concomitant medications. The mean D-2 occupancy at 5 mg was 59.8% (range 33-81%); the mean D-2 occupancy at 20 mg was 82.8% (range 56-97%). Although the D-2 occupancy rates on 5 and 20 mg olanzapine were significantly different (P < 0.001), there were no significant differences in clinical ratings for psychiatric symptoms or extrapyramidal side effects between the two doses of olanzapine. These data suggest that: (1) olanzapine doses below those used routinely occupy D-2 receptors at levels approaching those associated with therapeutic response; (2) higher doses produce relatively high levels of D-2 occupancy rates; and (3) EPS are mild even at relatively high levels of D-2 occupancy.
    Psychiatry Research Neuroimaging 04/1999; 90(2). DOI:10.1016/S0925-4927(99)00010-4 · 2.83 Impact Factor